The synthesis and secretion of an atriopeptin(AP)-like prohormone (AP126ir) has been demonstrated in rat neonatal renal cell cultures. AP126ir could be detected in the cellular extract and the medium from cultured kidney cells of neonatal and adult rats using an enzyme immunoassay specific for cardiac AP prohormone. On reverse-phase high-performance liquid chromatography, the AP obtained from the extract and the medium comigrated with cardiac AP prohormone. Incubation of the renal AP in the medium with thrombin resulted in the generation of a single low molecular mass peak which migrated with the cardiac carboxy-terminal 28-amino acid AP. Neonatal kidney cells pulsed with 135Simethionine secreted radiolabeled AP126ir, which was detected by immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis chromatography. Incubation of neonatal kidney cell cultures with the protein synthesis inhibitor cycloheximide resulted in a significant decrease in both the cellular and media AP. No decrease in cellular and media AP was detected when neonatal atrial cultures were treated with cycloheximide. These data demonstrate the de novo synthesis of an AP prohormone-like protein in neonatal rat kidney cultures. Furthermore, unlike the atria, kidney cells appear to secrete AP solely by constitutive means. In primary adult rat kidney cultures, most of AP126ir was detected in the cortical tubule fraction demonstrating that these cells secrete AP126ir in the adult rat kidney. We hypothesize that the renal AP may be important as an autocrine or paracrine regulator of renal function. (J. Clin. Invest. 1990. 87:208-212.).
Introduction
Atriopeptin (AP)' is synthesized in the mammalian atria and stored in atrial granules as a 126-amino acid prohormone (AP126) (1) . Secretion and processing occur simultaneously since the circulating form of AP is the 28-amino acid carboxyterminal fragment, AP28 (2) . The kidney is a major target organ for AP28 and produces an increase in renal blood flow, glomerular filtration rate, and natriuresis (3) . These effects are mediated by AP receptors in the kidney glomeruli and inner medulla (4) . Furthermore, the kidney is a major clearance organ for AP28 via its proteolytic degradation by a neutral endopeptidase in the proximal tubule brush border (5, 6) . Previous work in other laboratories have demonstrated the existence ofa low molecular mass AP in kidney extracts and urine (7, 8) .
Since there is a high AP receptor binding capacity in the kidney, it was presumed that this renal AP was ofblood origin. An amino-terminally elongated form ofAP28 in human urine has been demonstrated, suggesting that this peptide was derived from renal origin (9) . Our group has recently demonstrated AP immunoreactivity (APir) in the distal cortical nephron of rat kidneys (10) . To further evaluate renal AP synthesis and its mechanism of secretion, we chose to study this peptide in neonatal and adult rat kidney cultures.
Methods
Cell culture. Kidneys were obtained from 4-d-old Sprague-Dawley rats. Whole kidneys were minced and cells were dissociated in 0.1% trypsin in Hanks' buffered saline without calcium and magnesium. The cells were centrifuged at 500 g for 10 min, and the pellet was resuspended in Dulbecco's modified Eagle's medium (DME) supplemented with 10% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin, and 100 ,g/ml streptomycin. Cells were plated (2 X 106) in 35-mm diam wells (Becton, Dickinson & Co., Lincoln Park, NJ). Atrial and ventricular myocyte cell cultures were obtained from the atrial appendages and the ventricular apices of the neonatal rat heart, respectively. These cells were isolated in a manner identical to the above described kidney cultures and I X 106 cells were plated in 35-mm wells. The normal rat kidney (NRK) epithelial cell line (NRK-52E, 15th passage) was purchased from American Type Culture Collection, Rockville, MD. Rat mesangial cell cultures were generated according to the method of Lovett et al. (I 1). Kidneys from Sprague-Dawley rats (150 g) were removed and the isolated glomeruli were plated into wells and kept in RPMI 1640 medium, 5 mg/liter insulin, antibiotics, and 20% fetal calf serum. After 4 wk in culture, the remaining cell type consisted ofmesangial cells. To generate papillary collecting duct and cortical tubular epithelial cell cultures, papillae and cortex were excised from kidneys of adult Sprague-Dawley rats (150-200 g), respectively. Cells from papilla and cortex were dissociated in 0.1% type I collagenase (Worthington Biochemical Corp., Freehold, NJ) and 0.1% BSA Krebs-Henseleitbuffer for 120 and 45 min, respectively. To the papillary cell suspension 2 vol of distilled water were added and allowed to stand for 3 min before plating. The cortical cell suspension was filtered through a nylon filter (52-Am mesh opening, Spectrum Medical, Los Angeles, CA) to remove glomeruli. The absence of glomerular contamination was confirmed by microscopic visualization. Cells, both cortical and papillary, were plated on type IV collagen (50 gg/ml)-coated wells at a concentration of 2.5 X 105 tubule fragments per well. Experiments were done after I wk when cultures reached confluence. For AP determination, cultures were incubated in defined media. The defined media consisted of DME/F12 (1:1) supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 Ag/ml streptomycin, 15 mM Hepes, 35 mg/liter human transferrin, S mg/liter bovine insulin, 20 ,uM ethanolamine, 25 sM sodium selenite, and 0.3% BSA, essentially globulin free (Sigma Chemi-cal Co., St. Louis, MO). When cardiac AP prohormone (AP126) was incubated for 24 h in this media, no proteolysis was detected (unpublished observation). Cellular AP was extracted by boiling the cultures in 1 M acetic acid for 5 min followed by mechanical dissociation of the cells from the culture plates. After sonication and centrifugation (10,000 g for 3 min), the cellular supernatant was Iyophilized and stored at -20'C.
The cellular protein content was determined with a protein assay (Bio-Rad Laboratories, Richmond, CA).
AP assay. AP was determined by using a competitive enzyme immunoassay (EIA) as described previously (12) . In this assay, antibody (GP4) was used which had been raised in guinea pig against the rat AP sequence 103-126 (AP24). The cross-reactivity of this-assay for rat AP 126 was determined by the following procedure. The AP immunoreactivity (ir) was measured in a sample before and after incubation of AP126 with thrombin which selectively cleaves the AP prohormone between the amino acids Arg98 and Ser99 (13) . The incubation with thrombin resulted in the total conversion ofAP126 to AP28 which was confirmed by applying the sample to HPLC. Under these conditions we calculated a cross-reactivity of33% for AP126 as compared to AP24 using the GP4 antibody.
For measurement of AP126, we developed a highly specific and sensitive noncompetitive EIA sandwich assay. This assay was performed as follows. A monoclonal antibody (MRW9C6 1) raised in mouse against AP24 (14) was initially bound to 96-well plastic plates (6106L10, Thomas Scientific, Swedesboro, NJ) by overnight incubation (100 ug/ml). Nonspecific binding to the wells was minimized by preincubation of wells with 1% gelatin. Standards and samples were dissolved in EIA buffer (12) containing 0.1% BSA (essentially globulin free) and incubated overnight at 4°C. Next the plates were washed and guinea pig antibody (GP58), which had been raised against AP48-66 (amino acid sequence 48-66 ofthe AP prohormone), was added. After a second wash, the synthetic peptide AP48-66, which had previously been coupled to acetylcholinesterase, was added. The amount ofbound acetylcholinesterase was directly proportional to the amount ofAP 126 bound to GP58. Acetylcholinesterase activity was determined by the degradation of acetylthiocholine to acetate and thiocholine (12) .
Characterization ofkidney AP. AP Synthetic rat AP24 and thiorphan were obtained from Monsanto Co., St. Louis, MO. Reagents, if not specified otherwise, were purchased from Sigma Chemical Co. Rat AP126 was obtained from extracts of adult atria and purified by HPLC as described above.
Results
To validate the specificity of the AP126 EIA, standard curves using cardiac AP 126 were generated in the presence and absence of AP24 and AP48-66. As seen in Fig. 1 , the addition of 400 fmol per well ofAP24 or 250 fmol per well ofAP48-66 did not displace the prohormone standard curve. These results confirm the specificity of this assay for AP126. The lower limit ofdetection was -20 fmol/ml. The intra-and interassay coefficient ofvariability was determined to be 2.5% and 3.9%, respectively.
When neonatal kidney cells were incubated in secretion media for 24 h, we were able to detect -200 fmol/ml (35-mm well) of APir in the prohormone-specific EIA. Dilution of this secretion media resulted in a curve that paralleled authentic rat atrial AP 126 (Fig. 1) . To evaluate the secretion of the AP-like peptide from these kidney cells with respect to time in culture, cells were extracted on days 1,3,4,6, and 8 after plating. Before extraction cells were incubated in secretion medium for 24 h at 370C. The cellular content of AP126-like immunoreactivity (API26ir) increased from days 1 through 3 (4.2±0.1 to 6.8±0.3 fmol per well) after plating. On day 3, the cellular content ofAP was maximum. 24 h later, the cellular content of API26ir began to decline and reached a nadir on day 6 (2.5±0.2 fmol per well) (Fig. 2 A) . The increase in the cellular content ofAPI26ir from days 1 to 3 may reflect the increase in cell number since these cultures became confluent on day 2. However, the decline in AP content after day 3 does not reflect cell number since the cultures were easily maintained confluent for at least up to 14 d. The AP126ir secreted into the media, with respect to cell age, paralleled the cellular AP126ir content. Maximal AP126ir secretion occurred on day 3 (204±10 fmol per well 24 h) (Fig. 2 B) . Similar to the cellular content, secreted AP126ir began to decline on day 4 and reached its nadir on day 6 (22±2 fmol per well). Since AP28 undergoes degradation by proximal tubular brush border enzymes, and this degradation is inhibited by thiorphan, a neutral endopeptidase inhibitor (5), we evaluated whether thiorphan (10 MM) added to the media would increase the yield of AP126ir. No difference of the AP126ir concentration in the medium was found in the presence or absence of thiorphan as shown in Fig. 2 B. These data demonstrate that neonatal kidney cells secrete AP-like prohormone as detected in a prohormone-specific assay. The identity of this renal AP-like protein was further characterized by its migratory properties on reverse-phase HPLC. Chromatography of the cellular extract or the medium (Fig. 3 ) containing thiorphan showed a single peak coeluting with cardiac AP1 26. Deletion of thiorphan in the secretion medium resulted in the generation oftwo major peaks. Both peaks were detected by the prohormone-specific EIA, suggesting that one of the peaks may have been a truncated product ofthe AP-like peptide that maintained the recognition sites for the antibodies used in this assay. Incubation ofthe secretion medium with 10 ug/ml thrombin for 1 h at 370C resulted in the generation of a single peak, detected by the carboxy-terminal directed EIA, eluting at the position of AP28 (Fig. 3) . This peak could not be detected with the prohormone-specific assay. This demonstrates that the renal AP like protein, similar to atrial AP126, undergoes site-specific proteolysis by thrombin.
To evaluate the de novo synthesis ofthe AP-like peptide in neonatal kidney cell cultures, cells were incubated with radiolabeled methionine overnight before immunoprecipitation of the medium with GP4 antibody in the absence and presence of AP24. In lane I on SDS-PAGE chromatography (Fig. 4) , the renal APir migrated with an apparent molecular mass of 12.5 kD. The specificity of this band for AP is demonstrated by its absence when an excess of AP24 was added to the sample before immunoprecipitation (lane 2, Fig. 4) . The demonstration ofa specific high molecular mass radiolabeled band proves that renal APir is generated by de novo synthesis.
Atrial myocytes store AP in granules. Bloch demonstrated regulated secretion in atrial cell cultures and constitutive secretion in ventricular cell cultures by evaluating the amount ofAP secreted versus the content ofAP in cellular stores (15) . Similar to the data of Bloch et al. (15) , we determined media:cell AP ratios of0.02 and 0.53 in atrial and ventricular cultures, respectively (Table I) . Interestingly, the ratio in kidney cell cultures 24-h secretion medium followed by a 1-h incubation with thrombin at 370C. was determined to be 4.3, demonstrating little or no storage capacity for renal AP-like protein in these cells. To further evaluate the secretory pathway ofthe AP-like protein in neonatal kidney cells, we incubated neonatal atrial, ventricular, and kidney cell cultures with the protein synthesis inhibitor cycloheximide. We hypothesized that atrial cells, which have significant intracellular stores ofAP, would not decrease their cellular content or secretion rate of AP in response to a short incubation with cycloheximide. Cell cultures were preincubated with cycloheximide (5 MM) for 1.5 h. After this preincubation period, cells were incubated -for another 3.5 h with cycloheximide. The amount ofAP I 26ir secreted within this 3.5-h period as well as the cellular AP I 26ir and total cellular protein content was determined. In both heart and kidney cell cultures, the total cellular protein content declined 25% when compared to cultures which had not been incubated with cycloheximide (Fig. 5) . Cellular APir decreased 60% and 47% in kidney and ventricle cells after treatment with cycloheximide, respectively. APir was determined with the prohormone-specific assay. Each group is presented as mean±SEM (n = 4). The amount ofAPir secreted in the presence of cycloheximid decreased by 88% and 81% in kidney and ventricular cell cul tures, respectively. In contrast, cycloheximide had no effect ol either the cellular or media AP levels from atrial cell cultureE We excluded that the decrease in cellular and secreted APir ii ventricular and kidney cell cultures in response to cyclohexi mide was secondary to cell death, since the cells did not stai for trypan blue. Both the cellular content and the amount o secreted APl 26ir decreased in renal cell culture after the incu bation with cycloheximide, demonstrating that kidney cells se crete an AP-like peptide constitutively.
To evaluate the presence ofthe AP-like protein in adult ra kidney cell cultures, we examined NRK, primary papillary col lecting duct, primary mesangial, and primary cortical tubular cell cultures. API26ir was found in the conditioned medium o cultured NRK cells, papillary and cortical tubular cell cultures whereas no APl26ir was detected in mesangial cultures (Table   II) Our finding that this AP-like peptide is not stored in renal cells may explain why AP-like prohormone has not previously been detected in kidney extracts from normal rats (8) . These kidney extracts contained a considerable amount oflow molecular mass AP. In the heart, AP 126 processing occurs during or after secretion from the atrial myocyte. If the processing of the renal AP-like prohormone is analogous to the events in the atria, the renal low molecular mass AP may be partially derived from renal AP synthesis.
Atrial cells store AP in granules and release AP immediately after agonist stimulation. Because secretion of AP I 26ir in kidney cells appears to be solely constitutive, we hypothesize that the AP I 26ir secretion in the kidney, as in the cardiac ventricle, will not respond acutely to agonist stimulation. However, AP I 26ir secretion may be regulated by chronicly applied stimuli that may result in the changes of synthetic cellular capabilities.
Similarly to neonatal kidney cell cultures, we could demonstrate APl 26ir in primary adult kidney cell cultures and in the NRK cell line. Since most of the AP126ir was found in the cortical tubular fraction, cortical tubules may be the cell type responsible for synthesis of this renal AP-like peptide in the adult kidney.
The synthesis of AP in the heart (1), the release of AP from the atria into the circulation ( 16) and the diuretic action of AP in the kidney (3) has been well established. Beside this endocrine pathway of AP, we suggest the existence of a paracrine function of AP in the kidney. The role of this pathway in the physiology and pathophysiology of the kidney has to be evaluated in further studies.
